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FM Project: Increasing 
Naloxone Availability 
The Problem:
• Opioid abuse remains a major problem in U.S. public health. In 2013, 4.5 million people reported 
nonmedical use of prescription pain relievers in the prior month; 289,000 reported use of heroin.1
• Nationally, nearly 80 percent of people with opioid use disorder are 
not receiving treatment.2
• In Vermont, despite an expansion of  treatment Hub capacity, there 
remain significant waiting lists as all 7 treatment Hub sites and Spokes, 
thus increasing the likelihood of continued overdose deaths (graph 1). 3
• Nationally, in 2012, there were 16,007 deaths involving opioid 
analgesics and 5,925 involving heroin.4
• Despite the Vermont’s shift towards treatment-based approaches,
prescription overdose deaths continue at a steady rate, and heroin b
deaths are increasing (graph 2).5
The Problem: 
• Between 1996 and 2010, the CDC reported 10,171 successful opioid overdose reversals using the opioid 
antagonist naloxone. 6
• Intranasal naloxone has been shown equally effective to I.V. dosing and confers a preferable  safety 
profile in the pre-hospital emergent settings.7
• A retrospective study of naloxone administered by healthcare professionals and non healthcare 
professionals in Massachusetts found no difference in efficacy reversing overdose. 8
• Although Vermont’s Act 75 (2013) provides for expanded distribution of the drug, both prongs of the 
state’s strategy have faced obstacles: 
- First, despite the planned provision of doses to all emergency medical response teams, one of the state’s two largest police 
forces has resisted carrying the drug. 
- Second, despite the free distribution of naloxone at 7 treatment hubs, multiple sites report significant shortages, and the 
escalation of price for the drug (63% in the last year) is likely to further limit the availability of free doses.
• Despite provisions in Act 75 (‘13) affording legal protections for physicians directly prescribing 
Naloxone to those in recovery, their family members, and persons who might find themselves in a 
position to help those who might overdose, providers at Stowe Family Practice (STFP) and their MAT 
team  colleagues were unaware of any physicians doing so in the state and were eager to research the 
necessary parameters for such a practice. 
Discussions With Partners:
• In order to better understand the problem, the author: 
- Attended the northern VT MAT (medically assisted treatment) team learning collaborative session 
to investigate other physician’s naloxone prescribing habits, the current role of treatment Hubs in 
naloxone distribution, and to consult with addiction experts from Dartmouth Hitchcock.
- Engaged with Michael Leyden, Deputy Director of Emergency Medical Services at the Department 
of Public Health, to better understand the Department of Health’s interpretation of provisions 
within Act 75 regarding legal protections for physicians wishing to prescribe naloxone.
- Engaged with local pharmacies to asses their: 
o (1) Current supplies of naloxone (none carried nor had any previously filled a prescription). 
o (2) Their willingness to carry the drug. 
o (3) Ability to acquire the necessary components (drug and atomizer are sold separately). 
o (4) The price at which they would sell the drug to someone without insurance. 
- Engaged with the Medicaid bureaucracy and the contractor charged with executing their 
reimbursements (Gould) to find the price for naloxone for those on Medicaid. 
Methodology & Intervention:
• Based on the information gathered and the direction of providers at STFP, the author: 
- Coordinated with a local pharmacy to begin stocking naloxone doses and Teleflex Mad 300 
atomizers. 
- Ordered sample atomizers to facilitate in office training of drug administration. 
- Drafted a memo to other MAT teams across the state describing current federal guidelines, 
provisions of Act 75 related the issue, and STFP practice related to the prescribing of naloxone. 
Results & Response Data:
• On April 14th, two days after a STFP methadone patient died of an overdose, the first prescription 
known to the author for prophylactic naloxone given to the family member of a current users was 
written in the state of Vermont.
• The physicians at STFP intend to start/continue prescribing naloxone to: 
- Current users. 
- Family members of current users. 
- Those who frequent settings where an overdose may occur. 
Evaluating Effectiveness & Limitations:
• Evaluation: 
- The continuity of care provided by the “Spoke” model allows for a thorough evaluation of this 
project’s efficacy. Patients undergoing MAT return to STFP at least monthly for urine analysis, 
counseling, and prescription refills. MAT team members plan to (1) confirm prescriptions are 
filled, and (2) track whether they are used. 
• Limitations: 
- This project is primarily limited by time. With more time, those involved would have liked to 
further investigate means of gaining financial support from the state to fund this program. 
Future Projects:
• Future projects might: 
- Analyze MAT team generated data on number of prescriptions written, number of prescriptions 
filled, and how frequently doses are used. This data can be compared with data collected from the 
Department of Health on use patterns from doses distributed by Hubs. 
- Seek to understand why more doctors have not yet moved to prescribe naloxone to those in 
recovery and those close to them.
- Seek to understand how the availability of naloxone impacts drug use behaviors.
- Seek to understand the street value of naloxone and the impact of wider availability of the drug on 
that street value.
- Seek to understand why some community groups have opposed making the drug more accessible 
in our community. 
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